Herriot Tabuteau Sells 31,261 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 31,261 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $170.38, for a total transaction of $5,326,249.18. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,231,677.02. This represents a 81.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Herriot Tabuteau also recently made the following trade(s):

• On Monday, January 5th, Herriot Tabuteau sold 78,703 shares of Axsome Therapeutics stock. The shares were sold at an average price of $171.28, for a total transaction of $13,480,249.84.
• On Tuesday, January 6th, Herriot Tabuteau sold 29,450 shares of Axsome Therapeutics stock. The stock was sold at an average price of $172.33, for a total value of $5,075,118.50.
• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The shares were sold at an average price of $148.18, for a total value of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The shares were sold at an average price of $144.59, for a total value of $7,121,346.68.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The stock was sold at an average price of $146.94, for a total value of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total value of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The shares were sold at an average price of $134.49, for a total value of $2,928,519.75.
• On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The stock was sold at an average price of $132.34, for a total transaction of $12,136,239.70.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $167.55 on Friday. Axsome Therapeutics, Inc. has a twelve month low of $79.19 and a twelve month high of $184.40. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The firm has a 50-day moving average of $150.22 and a two-hundred day moving average of $127.35. The company has a market capitalization of $8.45 billion, a price-to-earnings ratio of -35.88, a PEG ratio of 9.00 and a beta of 0.44.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The business had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. The firm’s quarterly revenue was up 63.2% on a year-over-year basis. As a group, analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Trading of Axsome Therapeutics

A number of hedge funds have recently made changes to their positions in AXSM. Allworth Financial LP grew its position in Axsome Therapeutics by 6.6% during the third quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock valued at $175,000 after purchasing an additional 89 shares in the last quarter. Moors & Cabot Inc. lifted its position in Axsome Therapeutics by 4.5% in the 2nd quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after buying an additional 100 shares in the last quarter. Meridian Wealth Management LLC boosted its stake in shares of Axsome Therapeutics by 0.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after buying an additional 103 shares during the period. GAMMA Investing LLC grew its holdings in shares of Axsome Therapeutics by 65.4% during the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after acquiring an additional 106 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Axsome Therapeutics by 1.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock worth $1,032,000 after acquiring an additional 107 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised its 2026 earnings estimates (Q2/Q3/Q4 and FY2026 to a combined $3.72 EPS) and reiterated a Buy with a $200 price objective, signaling expectations for stronger near‑term profitability and supporting higher valuation.
• Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can help underpin demand for the shares. Read More.
• Positive Sentiment: Market commentary points to late‑2025 FDA moves — acceptance of a supplemental filing for AXS‑05 (agitation in Alzheimer’s) and FDA support for an NDA filing for AXS‑12 (narcolepsy) — expanding potential indications and revenue runway. Read More.
• Neutral Sentiment: Morgan Stanley reaffirmed an “equal weight” view but lifted its price target to $204 (from $196), implying upside vs. current levels but stopping short of a buy endorsement. Read More.
• Negative Sentiment: Insider selling: CEO Herriot Tabuteau sold a large block of shares across Jan. 5–7 (totaling roughly 139,414 shares over multiple transactions), leaving him with ~7,229 shares — a >90% reduction in his direct holding. Large, concentrated CEO sales can create near‑term supply pressure and raise investor concerns about optics or liquidity needs. Read More.

Analyst Ratings Changes

A number of equities research analysts have recently commented on AXSM shares. Morgan Stanley downgraded Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a research report on Thursday. UBS Group upped their target price on Axsome Therapeutics from $163.00 to $248.00 and gave the company a “buy” rating in a report on Tuesday. Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. HC Wainwright boosted their price objective on Axsome Therapeutics from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Monday. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $220.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $192.35.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.